PETMED EXPRESS, INC.
11.10%
2,300,318
1040130
716382106
May 17, 2025
May 20, 2025, 03:04 PM
Reporting Persons (2)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| SilverCape Investments Limited | CO | 11.10% | 2,300,318 | 2,300,318 | 0 |
| Peter Kennedy | Individual | 11.10% | 2,300,318 | 0 | 2,300,318 |
Disclosure Items (7)
Common Stock, $.001 Par Value
PETMED EXPRESS, INC.
700 NW 1st Avenue, Miami, FL, 33136
This Schedule 13D is being filed jointly by SilverCape Investments Limited ("SilverCape") and Peter Kennedy ("Kennedy"). The foregoing persons are hereinafter sometimes referred to collectively as the "Reporting Persons."
The principal business address of the Reporting Persons is c/o Trident Trust Company (Cayman) Limited, Fourth Floor, One Capital Place, P.O. Box 847, George Town, Grand Cayman KY1-1103, Cayman Islands.
The principal business of SilverCape is to be an investment company. The principal business of Kennedy is to serve as the Managing Director of SilverCape.
During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which any of the Reporting Persons was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
SilverCape is organized under the laws of the Cayman Islands. Mr. Kennedy is a citizen of the United States.
The Reporting Persons purchased the shares of Common Stock covered by this Schedule 13D in open market purchases for an aggregate purchase price of $10,332,118. The source of the Reporting Persons' payment of the purchase price for each purchase of shares of Common Stock covered by this Schedule 13D was working capital of SilverCape.
As of the filing date of this Schedule 13D, SilverCape is the holder of record of 2,300,318 shares of Common Stock, representing approximately 11.1% of the shares of Common Stock currently issued and outstanding. Kennedy, as the managing director of SilverCape, has voting and investment power with respect to the Common Stock held by SilverCape. Kennedy disclaims any beneficial ownership of the Common Stock beneficially owned by SilverCape.
SilverCape has the sole voting and dispositive power over the shares of Common Stock held by it. Kennedy, as the managing director of SilverCape, has voting and investment power with respect to the Common Stock held by SilverCape. Kennedy disclaims any beneficial ownership of the Common Stock beneficially owned by SilverCape.
Except as set forth above, there have been no transactions in the Common Stock by the Reporting Persons during the past 60 days.
No person other than the Reporting Persons is known by the Reporting Persons to have the right to receive dividends from, or the proceeds from the sale of, the shares of Common Stock beneficially owned by the Reporting Persons.
Not applicable.
Except as otherwise described in this Schedule 13D and the Joint Filing Agreement attached hereto as Exhibit 1, (i) there are no contracts, arrangements, understandings, or relationships (legal or otherwise) among the persons named in Item 2 and between such persons and any person with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies
Exhibit 1Joint Filing Agreement, dated as of May 20, 2025.